Login:
Share:
Email Facebook Twitter

Finance & Stock Market News


U.S. HIV drug firm Koronis looks to London listing

Sun, 13th Mar 2011 10:56


By Ben Hirschler

LONDON, March 13 (Reuters) - Koronis Pharmaceuticals
, a privately held U.S. biotech firm working on a new kind of HIV drug, is looking to list in London later this year or early in 2012, its chief executive said.

Seattle-based Koronis -- pioneering a new HIV drug designed to accelerate mutation of the virus that causes AIDS to the point where it collapses -- needs around $15 million to take its experimental product to the next stage of clinical tests.

CEO Donald Elmer said he had been in talks with banks in London because raising small sums of that size was no longer feasible on the Nasdaq market in the United States, given the heavy costs of maintaining a listing there.

He aims to raise the cash needed to take Koronis's 'viral decay acceleration' drug KP-1461 into further mid-stage Phase II studies via either an initial public offering (IPO) on London's Alternative Investment Market (AIM) or by reversing into a listed entity with a cash balance.

'The practical problem today is that Nasdaq is out of reach for many companies that are at the size of Koronis and the AIM market is an ideal intermediate rung for company looking to raise 10-15 million pounds,' he said in a telephone interview.

So far, KP-1461 has been tested in short clinical trials on around 80 patients with no ill-effect. Now Koronis needs to conduct longer-term tests to see if it really can reduce the amount of virus circulating in patients' blood.

If it works, the new drug could mark a major change in HIV/AIDS treatment. Existing drugs all work by suppressing virus function and must be taken in life-long cocktail combinations. KP-1461 would be the first non-suppressive therapy.

Katherine Xu, an analyst at Wedbush Securities, said in a research note in January that the approach was potentially 'game changing' for the $12 billion-a-year HIV market, although it was still at a very early stage and therefore highly uncertain.

Leading players in HIV treatment at present include Gilead and ViiV Healthcare, a joint venture of GlaxoSmithKline and Pfizer.

Koronis has to date raised $43 million in a series of private fund-raisings. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm.

(Editing by Louise Heavens) Keywords: KORONIS HIV/

(ben.hirschler@thomsonreuters.com; Tel: +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net; www.twitter.com/reutersBenHir)

COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.


Related Shares: Glaxosmithkline (GSK).


Next Article: Clal Insurance Japan quake exposure 28 mln shekels

Back to Finance News


Sign up for Live Prices


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.